On FDA Critical Path, Device Industry Demands Independence From Pharma
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed objects to FDA's characterization of the device industry's product pipeline as endangered, asserting that the agency's model for determining development timelines is skewed toward drugs
You may also be interested in...
Critical Path Will Lead To Device Research Opportunities In ’06 – Woodcock
A formal Critical Path priority list to be released in the coming year will include device-focused initiatives, assured FDA Deputy Commissioner for Operations Janet Woodcock
Critical Path Will Lead To Device Research Opportunities In ’06 – Woodcock
A formal Critical Path priority list to be released in the coming year will include device-focused initiatives, assured FDA Deputy Commissioner for Operations Janet Woodcock
AdvaMed Distances Devices From Proposed Postmarket Surveillance Reforms
AdvaMed is continuing to draw attention to essential differences between medical device and drug postmarket regulation as FDA faces increased public scrutiny related to drug recalls